The application of allogeneic hematopoietic stem cell transplantation in relapsed/refractory lymphoma
10.3760/cma.j.cn115356-20210129-00027
- VernacularTitle:异基因造血干细胞移植在复发难治淋巴瘤中的应用
- Author:
Yanping LIU
1
;
Jianyong LI
;
Kourong MIAO
Author Information
1. 南京医科大学第一附属医院 江苏省人民医院血液科 210029
- Keywords:
Lymphoma;
Hematopoietic stem cell transplantation;
Recurrence;
Transplantation conditioning
- From:
Journal of Leukemia & Lymphoma
2021;30(7):385-388
- CountryChina
- Language:Chinese
-
Abstract:
The therapy of relapsed/refractory lymphoma is still a challenge, and high-dose chemotherapy combined with autologous stem cell transplantation, new drugs and cellular immunotherapy are the main treatment options. In recent years, the emergence of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation (allo-HSCT) and alternative donor have made allo-HSCT become a valuable option for relapsed/refractory lymphoma. The features of the disease, patients' clinical characteristics, selection of alternative donors, conditioning regimen and the management of transplantation-related complications affect the survival of patients after transplantation. The data of allo-HSCT in the treatment of relapsed/refractory lymphoma are mainly derived from retrospective reports of various transplantation centers, and a large number of prospective clinical trials are desperately needed to explore. There are still no consensus for the selection criteria of transplant patients, the timing of transplantation, the selection of graft source and transplantation conditioning. This paper reviews the current progress of the application of allo-HSCT in relapsed/refractory lymphoma.
